AstraZeneca Showcases New Hematology Data with 65 Abstracts at ASH 2025

AstraZeneca plc announced its expanded presence at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled for December 6-9, 2025. The company will present 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include updated results from a Phase I trial of surovatamig, a CD19xCD3 T-cell engager, in relapsed/refractory follicular lymphoma, and initial data from the DURGA-1 Phase Ib/II study of AZD0120, an investigational BCMAxCD19 CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. The results will be presented at the upcoming ASH congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251204822773) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)